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Abstract
Background: The Framingham Heart Study (FHS), founded in 1948 to examine the epidemiology
of cardiovascular disease, is among the most comprehensively characterized multi-generational
studies in the world. Many collected phenotypes have substantial genetic contributors; yet most
genetic determinants remain to be identified. Using single nucleotide polymorphisms (SNPs) from
a 100K genome-wide scan, we examine the associations of common polymorphisms with
phenotypic variation in this community-based cohort and provide a full-disclosure, web-based
resource of results for future replication studies.
Methods: Adult participants (n = 1345) of the largest 310 pedigrees in the FHS, many biologically
related, were genotyped with the 100K Affymetrix GeneChip. These genotypes were used to
assess their contribution to 987 phenotypes collected in FHS over 56 years of follow up, including:
cardiovascular risk factors and biomarkers; subclinical and clinical cardiovascular disease; cancer
and longevity traits; and traits in pulmonary, sleep, neurology, renal, and bone domains. We
conducted genome-wide variance components linkage and population-based and family-based
association tests.
Results:  The participants were white of European descent and from the FHS Original and
Offspring Cohorts (examination 1 Offspring mean age 32 ± 9 years, 54% women). This overview
summarizes the methods, selected findings and limitations of the results presented in the
accompanying series of 17 manuscripts. The presented association results are based on 70,897
autosomal SNPs meeting the following criteria: minor allele frequency ≥ 10%, genotype call rate 
≥ 80%, Hardy-Weinberg equilibrium p-value ≥ 0.001, and satisfying Mendelian consistency. Linkage
analyses are based on 11,200 SNPs and short-tandem repeats. Results of phenotype-genotype
linkages and associations for all autosomal SNPs are posted on the NCBI dbGaP website at http://
www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000007.
Conclusion: We have created a full-disclosure resource of results, posted on the dbGaP website,
from a genome-wide association study in the FHS. Because we used three analytical approaches to
examine the association and linkage of 987 phenotypes with thousands of SNPs, our results must
be considered hypothesis-generating and need to be replicated. Results from the FHS 100K project
with NCBI web posting provides a resource for investigators to identify high priority findings for
replication.
Background
Cardiovascular diseases are major illnesses among Ameri-
cans, affecting about a third of the population (79 million
with prevalent disease) and resulting in more than
870,000 cardiovascular disease deaths annually [1]. Car-
diovascular disease and its risk factors have substantial
genetic contributors [2-11]. Numerous reports from the
Framingham Heart Study (FHS) have documented that
coronary heart disease [12,13], blood pressure [14-16],
lipids [17-20], diabetes [21-23] and weight [24,25] have
substantial heritability and linkage/association to specific
genomic regions. To evaluate the genetic contributors to
these phenotypes, the Framingham Heart Study con-
ducted a genome-wide scan of 1345 study participants in
two generations, using genotyping from the 100K Affyme-
trix GeneChip Human Mapping Set.
In this manuscript, we summarize the strategies that we
pursued to conduct the 100K genome-wide study, provid-
ing an overview for a series of 17 companion manuscripts
(Table 1 of the Overview) describing associations with
specific collections of traits [26-42]. The primary purpose
of this project was to generate hypotheses regarding
genetic factors that may contribute to the wide spectrum
of phenotypic variables collected in the FHS through a
genome-wide approach. More specifically, we primarily
hypothesized that common genetic variants contributing
to phenotypic variation can be detected through a
genome-wide association study (GWAS) and that genetic
loci contributing to phenotypic variation can be detected
through linkage. Each manuscript also examines whether
the 100K analyses replicated previously reported associa-
tions with consistent evidence from the literature for some
specific traits. The main purpose of this series of publica-
tions is to describe the association results made available
for investigators and to direct readers to their free availa-
bility in the database of Genotype and Phenotype
(dbGaP) public repository http://www.ncbi.nlm.nih.gov/
projects/gap/cgi-bin/study.cgi?id=phs000007 at the
National Center for Biotechnology Information (NCBI),
where these comprehensive results are posted and may be
browsed in the context of multiple genomic tracks includ-BMC Medical Genetics 2007, 8(Suppl 1):S1 http://www.biomedcentral.com/1471-2350/8/S1/S1
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ing Entrez Gene, RefSeq, dbSNP, genetic markers, and
OMIM. The deposition of these data in a public repository
is consistent with the long tradition of publishing prelim-
inary results from the FHS to benefit the wider scientific
community.
To organize the evaluation of the rich resource of data col-
lected over nearly 60 years of follow up, we established a
set of "Phenotype Working Groups" that included clini-
cians, epidemiologists, geneticists, and biostatisticians.
These groups specified the traits to be studied, along with
covariate adjustment and subgroups for analyses. In all,
987 phenotypes were examined for association, 835 for
linkage. Some phenotypes are the same trait with different
covariate adjustments, at different examinations or evalu-
ated in different subgroups. For example, many traits were
evaluated with both age and sex adjustment as well as
with additional multivariable adjustments, yielding more
than one phenotype for analysis. Each manuscript in this
series provides a platform for the web posted results. Not
every trait is described in the manuscripts; rather, the pur-
pose of each manuscript is to introduce the trait areas and
to present a brief summary of the results. In the present
manuscript, we describe the general approach to analysis
of the traits, provide an overview of some results, and dis-
cuss the limitations of the studies.
Methods
Study sample
The Framingham Heart Study (FHS) began in 1948 with
recruitment of 5209 men and women (2336 men and
2873 women) between the ages of 28 and 62 years in the
town of Framingham, Massachusetts, about 20 miles west
of Boston [43-46]. These individuals were recruited
through a two-thirds systematic sample of the households
of Framingham, Massachusetts. Although not initially
intended as a family study, many households consisted of
spouse pairs (1644 pairs). The primary purpose of the
Study was to follow individuals over time for develop-
ment of cardiovascular disease events to evaluate the
interplay among multiple risk factors that lead to disease
and their individual and joint effects. The participants in
the Original Cohort have been examined every two years
since.
In 1971, an Offspring Cohort of 5124 men and women,
who were adult children of Original Cohort members or
were spouses of these offspring, was recruited and has
been examined every four to eight years since [47,48]. The
subjects in this report are drawn from the largest 310 ped-
igrees in these two generations. The participants were
recruited without regard to phenotypes. Thus, the Off-
spring Cohort of 5124 (2483 men and 2641 women) was
recruited by inviting all offspring of the spouse pairs
(2616 and 34 stepchildren), the offspring spouses (1576)
and, additionally, those offspring (898) of singleton Orig-
inal Cohort members with elevated lipid levels. Further
information regarding recruitment can be seen in Cupples
et al. [49] and Dawber [43].
In the late 1980s and through the 1990s, DNA was col-
lected from living study participants. As many of the Orig-
inal Cohort members were deceased by that time, these
DNAs were mostly collected in Offspring Study partici-
pants. During the mid- to late-1990s, 1702 DNA samples
were genotyped by the Mammalian Genotyping Service in
the largest 330 two-generation pedigrees consisting of
2885 Framingham Study participants. These pedigrees
were used for linkage analyses of blood pressure [15], lip-
ids [17,50], body mass index [25] and a wide variety of
other traits [51-56]. The numbers of relative pairs among
the 1345 subjects both genotyped and phenotyped in this
study are 435 parent-offspring pairs, 988 sib pairs, 300
avuncular pairs and 634 first-cousin pairs. Among the
1087 Offspring Cohort participants, who were the only
participants evaluated in some analyses, there were 936
sib pairs, 63 avuncular pairs and 612 first-cousin pairs.
Original Cohort study subjects return to the Study every
two years for a detailed medical history, physical examina-
tion and laboratory tests. The Original Cohort subjects are
currently in their 29th examination. Participants in the
Offspring Cohort return every 4 to 8 years for similar
examinations and the 8th examination is currently under-
way.
In the early 2000s, a family DNA plate set with 1,399 par-
ticipants from these 330 pedigrees http://
www.nhlbi.nih.gov/about/framingham/policies/
index.htm was established. Only subjects with lymphob-
last cell lines were included on the plate set, although a
substantial number of the DNA samples on the plate set
were derived from whole blood or buffy coat. The family
plate set was used for genotyping of the Affymetrix 100K
GeneChip. After cleaning the genotyping data, the study
sample comprised 1345 FHS participants, 278 from the
Original and 1087 Offspring Cohorts.
Phenotype definition & methods
Given the breadth of phenotypes, we established 8 larger
Phenotype Working Groups, overseeing 17 discrete phe-
notypic domains, as follows: 1. Blood pressure, arterial
stiffness, echocardiography, endothelial function and
exercise testing; 2. Metabolic traits including anthropom-
etry, glycemic traits and lipids; 3. Pulmonary function and
sleep; 4. Systemic biomarkers, including inflammatory
and thrombotic factors; 5. Subclinical atherosclerosis; 6.
Renal and endocrine function; 7. Longevity and aging,
including brain and bone aging phenotypes; 8. Cardiovas-
cular disease outcomes, cancer, electrocardiography andBMC Medical Genetics 2007, 8(Suppl 1):S1 http://www.biomedcentral.com/1471-2350/8/S1/S1
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heart rate variability. In addition, we established a statisti-
cal and analytical methodology group. These groups were
convened by the FHS Genetic Steering Committee to
define phenotypes to be evaluated, including the covari-
ates used in analyses, to review results of linkage and asso-
ciation analyses, to foster communication among various
Framingham investigators who were working on different
traits, and to suggest possible follow-up strategies.
For the 100K genome-wide project, each Working Group
defined the phenotypes to be studied. Since most traits
have well established factors that contribute to their vari-
ation, each group created a set of residuals from multivar-
iable regression models accounting for the primary
known covariates, in order to control for confounding
from these variables and to increase the ability to detect
genetic signals. For quantitative traits, the adjusted stand-
ardized residuals were generated using linear regression
models. For qualitative traits, we used a variety of
approaches including Cox proportional hazards with
Martingale residuals for time-to-event (survival) traits and
logistic regression with deviance residuals for dichoto-
mous traits. These methods are described below. In some
cases, several different covariate adjustments were used
for a single trait. Each manuscript describes the specific
adjustments that were applied. We used residuals from
regression models that included all subjects with traits in
each Cohort, rather than limiting analyses to those who
were genotyped, to produce residuals based on all subjects
with phenotypic values, regardless of availability of geno-
typic data. This approach avoids potential biases in covari-
ate adjustment based only upon the subset of individuals
with both genotype and phenotype data and produces
robust estimates of covariate effects.
Genotyping methods
Genomic DNA derived from whole blood or buffy coat
was phenol-chloroform extracted and DNA from immor-
talized lymphoblast cell lines was salt-precipitate
extracted. Genotyping of the 100K SNPs in FHS families
was performed through an ancillary study to Drs. Michael
Christman and Alan Herbert at Boston University School
of Medicine in the Department of Genetics and Genomics
using the GeneChip Human Mapping 100K set from
Affymetrix, following the manufacturer's protocol as pre-
viously described [57]. Genotypes were determined using
the Dynamic Modeling (DM) algorithm [58]. For linkage
analyses, we also included microsatellites that had been
genotyped by the NHLBI Mammalian Genotyping Serv-
ice, Center for Medical Genetics, Marshfield Medical
Research Foundation http://research.marshfield
clinic.org/genetics. A set of 401 microsatellite mark-
ers)[59], covering the genome at an average density of one
marker every 10 cM and with an average heterozygosity of
0.77, were genotyped in 1702 subjects in the mid to late
1990s (Screening Set v. 8))[60]. An additional 190 partic-
ipants on the Family Plate Set were genotyped later with
microsatellites using Screening Set v.13 and some addi-
tional microsatellites were also genotyped in the FHS
Genetics Laboratory. With the addition of these microsat-
ellites and changes in the marker sets from Set 8, there
were 613 microsatellite markers available for analysis.
Table 1: Papers published in the Framingham Heart Study 100K Series
First Author Title
Ramachandran S. Vasan Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill 
exercise responses in the Framingham Heart Study
Daniel Levy Framingham Heart Study 100K Project: genome-wide associations for blood pressure and arterial stiffness
Christopher J. O'Donnell Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's 
Framingham Heart Study
Martin G. Larson Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes
Joanne M. Murabito Genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study
Christopher Newton-Cheh Genome-wide association study of electrocardiographic and heart rate variability traits: the Framingham Heart Study
Jemma B. Wilk Framingham Heart Study genome-wide association: results for pulmonary function measures
Daniel J. Gottlieb Genome-wide association of sleep and circadian phenotypes
Shih-Jen Hwang A genome-wide association for kidney function and endocrine-related traits in the NHLBI's Framingham Heart Study
Emelia J. Benjamin Genome-wide association with select biomarker traits in the Framingham Heart Study
Qiong Yang Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the 
Framingham Heart Study
Kathryn L. Lunetta Genetic correlates of longevity and selected age-related phenotypes: a genome-wide association study in the 
Framingham Study
Douglas P. Kiel Genome-wide association with bone mass and geometry in the Framingham Heart Study
Sudha Seshadri Genetic correlates of brain aging on MRI and cognitive test measures: a genome-wide association and linkage analysis 
in the Framingham study
James B. Meigs Genome-wide association with diabetes-related traits in the Framingham Heart Study
Sekar Kathiresan A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study
Caroline S. Fox Genome-wide association to body mass index and waist circumference: the Framingham Heart Study 100K projectBMC Medical Genetics 2007, 8(Suppl 1):S1 http://www.biomedcentral.com/1471-2350/8/S1/S1
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Statistical analysis methods
Data cleaning
A total of 1380 individuals were successfully genotyped.
First, familial relationships were checked using the
sib_kin utility in the Aspex software package [61]. Because
this study focused on participants of families, nine indi-
viduals were excluded as they no longer had biologic rel-
atives in the sample. Twenty-six individuals were excluded
due to inconsistencies; the majority of these individuals
were found to have an excessive number of Mendelian
errors as identified by the software PedCheck, Version 1.1
[62]. Others were excluded for having a relationship
inconsistency, for a sex discrepancy or for a low genotyp-
ing call rate. Mendelian inconsistencies were resolved by
removing the genotypes of all individuals within nuclear
families in which the error occurred. These steps left 1345
individuals with genotypes available for analyses.
For Hardy-Weinberg equilibrium (HWE) testing, we ran-
domly selected one individual per family to form a sam-
ple of unrelated individuals. Then, for each of the 100K
SNPs, the observed genotype frequencies were compared
to those expected under HWE using an exact chi-square
test statistic [63] implemented in the Genetics package
[64] in R, Version 1.2.0 [65]. To guard against a result that
might depend upon an unusual selection of individuals,
we repeated this process of a random selection of subjects
ten times and computed the geometric mean of the ten p-
values for the ten random samples of individuals as the
final p-value for HWE tests for each SNP. Tests for HWE
that indicate a SNP is far from HWE suggest that the SNP
may have issues with genotyping error.
We found 38,062 SNPs with MAF <10% (of which 3084
autosomal SNPs were monomorphic), an additional
2346 SNPs with genotyping call rates <80% and still
another 1595 with HWE p-value < 0.001. We used a gen-
otyping call rate cutpoint of 80% in part because of the
use of the less accurate DM algorithm. SNPs with low
MAF, low genotyping call rates and inadequate HWE pro-
duced unstable results, so they were excluded from our
association results reported in this set of manuscripts,
leaving 70,987 SNPs. Results for all autosomal SNPs are
reported on the dbGaP website, regardless of MAF, geno-
typing call rates or HWE p-values; however, filters for
these factors are provided on the dbGaP website.
Linkage analyses
Both microsatellites previously genotyped by the Mam-
malian Genotyping Service and SNPs from the 100K were
used to calculate identity by descent probabilities. We
constructed genetic maps using all microsatellite NCBI
genetic markers with Marshfield genetic location available
and whose physical order and genetic order were consist-
ent. Using this NCBI Marshfield map as our skeleton, we
applied linear interpolation from physical to genetic dis-
tance to obtain approximate genetic locations (in centi-
Morgans) for all SNPs in the 100K set with known
physical location.
Because current linkage analysis software cannot handle
the marker density available from a 100K scan, we
selected a subset of 10,592 SNPs to supplement 613
genome scan microsatellite markers available on 1886
members of the largest 330 Framingham families. We
selected SNPs to minimize linkage disequilibrium (LD)
because current linkage software assumes that markers are
in linkage equilibrium, and violation of this assumption
has been shown to create spurious linkage evidence in cer-
tain contexts [66,67]. Thus, for calculation of identity by
descent (IBD) probabilities for linkage analyses we used
SNPs with a call rate of at least 85%, HWE p-value > 0.05
and more informative markers with MAF > 5%. We itera-
tively identified SNP pairs with LD measure D' > 0.5, as
estimated from HapMap data, and eliminated the SNP
that was least informative for linkage (lowest MAF). We
started with SNP pairs most closely located (physical dis-
tance) and continued until no pairs of SNPs had a D'
measure exceeding 0.5. The final set of 10,592 SNPs com-
bined with the 613 microsatellites were checked for excess
recombination using MERLIN, Version 0.10.2 [68], and 4
SNPs and 1 microsatellite were omitted from linkage anal-
yses based on a high number of possible errors, leaving a
total of 11,200 markers to perform linkage analysis
(10,588 SNPs + 612 short tandem repeats).
Variance component linkage analyses were performed on
residuals of up to 1341 individuals in 310 full pedigrees.
Four of the 1345 subjects were the only person in a pedi-
gree and were excluded from linkage analyses since they
contributed no information. Multipoint probabilities of
IBD between relative pairs were computed at each genetic
marker location with the program MERLIN, Version
0.10.2. Due to size limitations for exact identity by
descent (IBD) multipoint computation in MERLIN soft-
ware [68], the 310 full pedigrees were broken into 356
smaller pedigrees. The hypothesis of "no linkage at a spe-
cific genomic location" was tested by comparing models
incorporating an effect of a putative quantitative trait
locus (QTL) in complete linkage to the genetic marker, in
the form of multipoint IBD sharing probabilities at the
locus, to models incorporating only polygenic effects
without a QTL effect. At each genetic location, a LOD
score was computed as the logarithm to base 10 of the
likelihood ratio of the locus-specific model to the poly-
genic model using the program SOLAR, Version 3.0.4
[69]. Allele frequencies were estimated by simple allele
counts. In Framingham family data, which were collected
from randomly sampled pedigrees, we have found the
allele frequency estimates by simple allele countingBMC Medical Genetics 2007, 8(Suppl 1):S1 http://www.biomedcentral.com/1471-2350/8/S1/S1
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closely match those calculated by maximum likelihood
methods accounting for familial correlations.
Association testing
We applied population-based and family-based methods
to test for association between the 100K SNPs and resid-
ual phenotypes using an additive model unless otherwise
specified. We used family-based association test methods,
implemented in the program FBAT, Version 1.5.5 [70,71],
to test for differences in probability of transmission of a
genotype from parents to offspring based on phenotype,
as a test of linkage and association. FBAT has limited
power because it requires association within families, and
many families are non-informative. However, because
FBAT examines association only within families, the type-
I error rate is not affected by population stratification
bias)[72,73]. We did not report results if the number of
informative families was fewer than 10.
For the population-based approach, we used generalized
estimating equation (GEE) [74] regression models to test
for association between the 100K SNPs and each residual
phenotype while taking into account the correlation
among related individuals. We implemented the GEE
approach by breaking families into sibships and used an
exchangeable working correlation matrix to account for
correlation within each sibship. Parental correlations with
their children were not considered in these analyses. The
analyses were performed using the gee program package,
Version 4.13-10 [75] in R [65]. The GEE association test is
a population-based approach that uses all individuals
with both genotype and phenotype, regardless of geno-
type configuration within a family. Therefore, it is
expected to be a powerful test of association if population
stratification bias is not believed to be an issue, as in the
FHS [76].
Results
Participant characteristics
Of the 1345 subjects who satisfied appropriate familial
relationships and who were considered in the presenta-
tion of results in these manuscripts, 258 were Original
Cohort participants (90 men and 168 women) and 1087
were Offspring Cohort participants (527 men and 560
women). Table 2 of the Overview presents descriptive
information on these participants at enrollment (exami-
nation one). The Offspring and Cohort participants
included on the family plates had lower mean age than
other examination 1 participants, as these subjects needed
to survive to the mid 1990s to provide DNA. We note that
we used residuals based upon all subjects, as opposed to
only those who were genotyped. Thus, the phenotypes
reflect deviations of these subjects based on regressions
for the full sample of subjects and are thus representative
of the full sample.
Format of the FHS 100K manuscripts
We present 17 manuscripts, each displaying selected
results for an epidemiologically related group of traits.
Table 1 of the Overview presents the title and first author
of each manuscript. The web resource displaying genetic
association and linkage results is available at the NCBI
dbGaP website, http://www.ncbi.nlm.nih.gov/projects/
gap/cgi-bin/study.cgi?id=phs000007. Each manuscript
describes the traits that were studied and presents some
results. These manuscripts are not intended to be compre-
hensive and generally do not include results for all pheno-
types and covariate adjustment schemes that were studied
and presented on the website. Full listings of all traits eval-
uated are provided in Additional file 1 (phenotypes for
population-based GEE analyses), Additional file 2 (phe-
notypes for family-based FBAT analyses) and Additional
file 3 (phenotypes for linkage analyses), including url
links to the corresponding analytical results on the NCBI
dbGaP website. To facilitate the reading of these manu-
scripts, we have used a common format for all manu-
scripts. Table 1 of each manuscript presents a general
description of the phenotypes that were evaluated. Table
2 of each manuscript displays the top results (lowest p-
values) from GEE analyses, the top results (lowest p-val-
ues) from FBAT analyses and linkage results where the
LOD score was 2 or more. Whereas top association results
are based solely on p-value rank, the Working Groups also
applied various additional strategies to identify SNPs that
the group would prioritize to pursue further. For Table 3
of each manuscript, the groups devised schema to sum-
marize results for related traits, grouping phenotypic traits
within biologically plausible domains, or traits examined
longitudinally. Each manuscript provides a description of
the strategy employed and the results for its Table 3.
Finally, Table 4 in each manuscript lists some SNPs that
are the same as or correlated with genetic variants in genes
that have been reported in the literature to be associated
with the manuscript's phenotypes and indicates whether
our results replicate those reports. Physical locations of
the SNPs are provided according to NCBI Build35,
whereas the dbGaP website uses a more recent version.
Thus, the physical locations reported in the manuscripts
may differ from those on the website. Each manuscript
provides criteria for choosing which results were reported.
SNP allele frequencies and distribution
Allele frequencies for the 100K Affymetrix GeneChip in
the Framingham sample are displayed in Figure 1. About
38% have MAF < 10% and are not considered in the series
of manuscripts, although they are included on the dbGaP
website. Among SNPs with MAF ≥ 10%, there were large
numbers between 10–25% and were somewhat evenly
spread over the range from 25–50% MAF. Many SNPs on
the Affymetrix Chip are not near genes (Figure 2). About
30,000 with MAF ≥ 10% are within 5 kb of a gene; anotherBMC Medical Genetics 2007, 8(Suppl 1):S1 http://www.biomedcentral.com/1471-2350/8/S1/S1
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10,000 with MAF < 10% are within 5 kb. The remaining
SNPs are further away from known genes.
P-value distribution
The results displayed on the NCBI dbGaP http://
www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
study.cgi?id=phs000007 include all autosomal SNPs,
regardless of genotyping call rate, HWE p-value or MAF;
adjustable filters for these factors are provided. In our
manuscripts, we present results for SNPs that satisfy geno-
typing call rates ≥ 80%, HWE p-value ≥ 0.001, and MAF 
≥ 10%. The proportion of SNPs satisfying a genotyping
call rate of ≥80% is 97.4%; 91% of SNPs satisfied a call
rate of ≥90%.
We expect only a small percentage of all tested SNPs to be
truly associated with any phenotype. Therefore, to obtain
an approximation of the null distribution of p-values, we
examined the distribution of p-values for 415 phenotypes
from the Metabolic Working Group and 14 CVD event
phenotypes. If one assumes that only a few true associa-
tions exist for each phenotype, these p-value distributions
approximate the null distribution, because only a few
SNPs out of the large total number tested would be
expected to exceed any critical value due to true associa-
tions. Table 3 of the Overview displays the proportion of
p-values among all SNPs below specific nominal alpha
levels, summarized (mean, minimum and maximum)
across all phenotypes in the trait group for GEE and FBAT
results.
Many of the phenotypes in the Metabolic Working Group
were approximately normally distributed (about 90% had
absolute value of skewness <1 and about 80% had abso-
lute value of kurtosis <2) and thus may reflect the situa-
tion for which the assumptions of the analytical methods
were generally satisfied. We display two sets of results in
Table 3 of the Overview for these phenotypes, those used
in the publication of the manuscripts with the number of
SNPs equal to 70,987 and the larger set of results dis-
played on the website with the number of SNPs equal to
~100–103 K. The difference in the number of SNPs evalu-
ated for GEE and FBAT results arises from those SNPs that
are uninformative for FBAT analyses (those with suffi-
ciently rare minor allele so that fewer than 10 nuclear fam-
ilies were informative for transmission). The p-value
distributions suggest that FBAT p-values generally follow
the expected null distribution, assuming that nearly all
results are false positives, and may actually be somewhat
conservative. In contrast, the GEE p-values exhibit an
excess of small p-values, especially for smaller nominal
alpha levels. For example, for SNPs reported in the manu-
scripts, the average proportion of SNPs for a phenotype
with p-value below specified alpha levels ranged from 1.3
to 19 times greater than the nominal level (1.3 times
larger for nominal alpha of 0.01, 19 for nominal alpha of
10-7 and 10 for 10-8). The excess is higher for the full set of
SNPs reported on the website. Here we found that the
average proportion ranged from 1.2 times larger for nom-
inal level of 0.05 to 19 times greater for nominal level of
10-5 and 2500 times greater for nominal level 10-8.
The CVD phenotypes represent an extreme case, as the
phenotypes were residuals from survival models, were
generally bimodal, and do not satisfy general assumptions
for normality. We see the same general pattern that we
observed for the Metabolic Working Group phenotypes
with somewhat conservative FBAT tests and excess num-
Table 2: Description of Framingham Heart Study Subjects in 100K Genome-Wide Scan. 
Baseline Data at Exam 1 for Original (1948–1951) and Offspring (1971–1975) Cohorts
Original Cohort Men Original Cohort Women Offspring Cohort Men Offspring Cohort Women
N = 90 N = 168 N = 527 N = 560
Age, years 35 ± 4 35 ± 4 31 ± 10 32 ± 10
(Limits) (30–46) (29–48) (11–62) (5–59)
Body Mass Index, kg/m2 25.7 ± 3.2 23.9 ± 3.6 26.0 ± 3.9 23.6 ± 4.3
Obese (BMI 30 ≥kg/m2), % 7.8 6.0 13.3 8.2
Systolic Blood Pressure, mm Hg 129 ± 13 120 ± 12 124 ± 14 115 ± 14
Diastolic Blood Pressure, mm Hg 81 ± 9 76 ± 8 81 ± 10 75 ± 10
Antihypertensive Medication, % 0 0 1.7 1.4
Hypertension, % 22.2 8.9 15.0 6.8
Current Smoking, % 61.1 42.3 40.0 41.3
Blood Glucose, mg/dL 78 ± 13 78 ± 11 102 ± 10 97 ± 9
Prevalent Diabetes, % 0 0 0.6 0.4
Total Cholesterol, mg/dL 220 ± 44 194 ± 37 192 ± 37 185 ± 36
HDL Cholesterol, mg/dL N/A N/A 44.9 ± 11.0 56.4 ± 13.9
Lipid Lowering Medication, % 0 0 0.2 0.5
Hemoglobin, g/dL 14.3 ± 1.2 12.3 ± 1.1 15.5 ± 1.0 13.5 ± 1.0
Forced Vital Capacity, dL 40 ± 7 28 ± 6 45 ± 8 32 ± 5
Prevalent CVD, % 0 0 5.5 2.6
Abbreviations: BMI = body mass index; HDL = high density lipoprotein; CVD = cardiovascular disease.BMC Medical Genetics 2007, 8(Suppl 1):S1 http://www.biomedcentral.com/1471-2350/8/S1/S1
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bers of small p-values for GEE tests. As might be expected,
the CVD phenotypes revealed larger excesses of small GEE
p-values, with the average proportion of SNPs falling
below specified alpha levels ranging from 1.08 (5.4% for
nominal 5% with SNPs reported in the manuscripts) to
2.4 times greater for nominal level of 10-5 and 67 times
greater for nominal 10-8 than expected. Thus, GEE p-val-
ues need to be interpreted with care, as SNPs in the lowest
p-value range have the potential to be especially enriched
with false positives.
We also examined the dependence of the p-value distribu-
tion for GEE results on the genotyping call rate for the
Metabolic Working Group phenotypes. Our sample was
not ascertained on trait status; so genotyping failures were
likely to be randomly distributed. Therefore, one might
expect that the effect of genotyping error on type I error
would be more modest than for case-control studies)[77].
As expected, we continued to find an excess of small p-val-
ues, despite increasingly stringent call rate thresholds.
More importantly, we found that this excess occurred
regardless of call rate. For example, for nominal alpha of
0.001 and genotyping call rate > 95%, we found that the
ratio of the number of observed to expected significant
results ranged from 1.6 for MAF in the range of (0.2, 0.5)
to 7.0 for MAF in the range (0, 0.05). Similarly, for call
rate less than 80% we found similar ratios of 1.6 to 8.1,
respectively. For nominal alpha of 10-6 we found this ratio
varied from 9.5 to 614 for call rate > 95% and 6.8 to 667
for call rate < 80%. Thus, we used a liberal genotyping call
rate of > 80% for presentation of results in our manu-
scripts to err on the side of including a result rather than
not, even though we expect nearly all results to be false
positives.
Table 3: Proportion of p-values falling below nominal levels for selected traits
SNPs with MAF ≥ 10%, HWE p ≥ 0.001 and Genotyping Call Rate ≥ 80%
Nominal alpha level
# SNPs 0.05 0.01 0.001 1 × 10-4 1 × 10-5 1 × 10-6 1 × 10-7 1 × 10-8
Metabolic Traits*
Mean† FBAT 70987 0.050 0.010 8.5 × 10-4 7.3 × 10-5 5.1 × 10-6 6.1 × 10-7 1.4 × 10-7 0
Min† FBAT 0.046 0.008 4.4 × 10-4 00000
Max† FBAT 0.056 0.012 1.5 × 10-3 2.7 × 10-4 5.6 × 10-5 4.2 × 10-5 2.8 × 10-5 0
Mean GEE 70987 0.058 0.013 1.6 × 10-3 2.3 × 10-4 3.7 × 10-5 7.9 × 10-6 1.9 × 10-6 1.0 × 10-7
Min GEE 0.051 0.010 9.2 × 10-4 5.6 × 10-5 0000
Max GEE 0.081 0.022 3.3 × 10-3 6.6 × 10-4 1.4 × 10-4 8.5 × 10-5 5.6 × 10-5 1.4 × 10-5
CVD Events*
Mean FBAT 70987 0.050 0.009 6.6 × 10-4 4.4 × 10-5 4.0 × 10-6 000
Min FBAT 0.047 0.006 1.7 × 10-4 00000
Max FBAT 0.053 0.010 9.4 × 10-4 8.5 × 10-5 1.4 × 10-5 000
Mean GEE 70987 0.054 0.012 1.4 × 10-3 1.8 × 10-4 2.4 × 10-5 6.7 × 10-6 2.7 × 10-6 6.7 × 10-7
Min GEE 0.046 0.009 7.9 × 10-4 4.2 × 10-5 0000
Max GEE 0.062 0.015 2.5 × 10-3 5.9 × 10-4 1.3 × 10-4 5.6 × 10-5 2.8 × 10-5 1.4 × 10-5
All SNPs posted on website http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000007
Metabolic Traits*
Mean FBAT 100584 0.050 0.009 7.7 × 10-4 6.3 × 10-5 4.3 × 10-6 5.7 × 10-7 1.2 × 10-7 0
Min FBAT 0.046 0.008 4.4 × 10-4 00000
Max FBAT 0.054 0.011 1.3 × 10-3 2.2 × 10-4 5.0 × 10-5 3.0 × 10-5 2.0 × 10-5 0
Mean GEE 101944 0.061 0.015 2.4 × 10-3 5.5 × 10-4 1.9 × 10-4 8.4 × 10-5 4.3 × 10-5 2.5 × 10-5
Min GEE 0.052 0.012 1.5 × 10-3 1.9 × 10-4 3.0 × 10-5 000
Max GEE 0.082 0.025 1.1 × 10-2 6.8 × 10-3 4.3 × 10-3 2.6 × 10-3 1.7 × 10-3 9.4 × 10-4
CVD Events*
Mean FBAT 101060 0.048 0.008 5.9 × 10-4 3.5 × 10-5 3.3 × 10-6 000
Min FBAT 0.043 0.005 1.2 × 10-4 00000
Max FBAT 0.052 0.010 9.1 × 10-4 9.9 × 10-5 1.0 × 10-5 000
Mean GEE 103194 0.059 0.016 3.4 × 10-3 1.1 × 10-3 4.7 × 10-4 2.0 × 10-4 9.5 × 10-5 4.4 × 10-5
Min GEE 0.050 0.011 1.1 × 10-3 1.3 × 10-4 2.9 × 10-5 000
Max GEE 0.078 0.033 1.4 × 10-2 7.1 × 10-3 3.6 × 10-3 1.6 × 10-3 7.8 × 10-4 3.3 × 10-4
* There were 415 Metabolic Traits and 14 CVD Events from which these descriptive statistics were calculated using the # SNPs indicated. # SNPs = average number of SNPs 
across all traits in the Trait Group; †Mean = average proportion of SNPs below nominal level across phenotypes in the trait group; Min = minimum proportion below nominal 
level across phenotypes in the trait group; Max = maximum proportion below nominal level across phenotypes in the trait group.BMC Medical Genetics 2007, 8(Suppl 1):S1 http://www.biomedcentral.com/1471-2350/8/S1/S1
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Figure 3 displays observed GEE (blue) and FBAT (red) p-
values versus expected p-values (straight line) on a nega-
tive logarithm scale for mean fasting plasma glucose and
mean high density lipoprotein cholesterol, calculated
from Offspring measurements over exams 1 to 7. We see
that FBAT p-values tend to be less significant than
expected (conservative) whereas GEE p-values tend to be
more significant than expected (liberal), especially for
smaller expected p-values. While we would expect most p-
values to fall on the line if there were no genetic associa-
tions, p-values that reflect true associations will be more
extreme (smaller) than expected. In looking at the figure
for mean fasting glucose, SNPs represented by the blue
dots (GEE) far above the expected line on the right hand
side of the figure may represent true associations with
mean fasting plasma glucose. The plot for mean fasting
HDL cholesterol also suggests that there may be some true
positives, as even a few FBAT p-values are more extreme
than expected.
As in any GWAS, we expect that most results with small p-
values are false positives. The p-value distributions sup-
port this notion and further suggest that the GEE results
may have more false positives than one would expect.
Table 2 in each manuscript ranks results by p-value, but
each paper also pursues its own strategy to identify which
results may be more worthy of follow up in Table 3 of
each manuscript, usually by considering evidence from
several sources such as correlated traits.
Power estimations for population-based association 
approach
To assess the power of the population-based association
approach with GEE, we simulated a trait following a nor-
mal distribution with 30% polygenic heritability in this
sample of 1345 subjects. We generated a SNP with MAF
0.10 and assumed that the SNP was the QTL with an addi-
tive effect and QTL heritability varying from 1% to 5%.
We also varied the proportion of phenotyped individuals
from 60% to 100%, as some traits were not available in all
subjects genotyped. The phenotype and genotype data
were simulated using SOLAR simqtl, Version 3.0.4. We
tested the association between the SNP and the trait using
GEE. One thousand replicates were performed for each
scenario. The results are displayed in Table 4 of the Over-
view. For a conservative alpha level such as 10-8, we have
more than 80% power to detect a SNP explaining 4% or
more total phenotypic variation when 60% or more indi-
viduals are phenotyped. With higher MAF, the power
remains similar for the same QTL heritability (data not
shown). Thus, we have sufficient power to detect SNPs
explaining ≥4% or more of the phenotypic variance using
the population-based GEE association test approach, con-
trolling for multiple testing for a single trait. The effect size
for a specific QTL heritability, defined as the increase/
Table 4: Power of the population-based association approach (GEE test) for a SNP with MAF = 0.1
Nominal Type I Error
SNP QTL Heritability Effect Size (SD)* Model 0.05 0.01 0.001 10-4 10-5 10-6 10-7 10-8
100% phenotype available (n = 1345)
1% 0.24 GEE 0.977 0.919 0.78 0.60 0.43 0.27 0.17 0.10
2% 0.33 GEE 1 1.00 0.99 0.97 0.91 0.84 0.72 0.59
3% 0.41 GEE 1 1 1 0.998 0.992 0.985 0.957 0.918
4% 0.47 GEE 1 1 1 1 1 1 0.996 0.991
5 % 0 . 5 3 G E E 11111111
~80% subjects have phenotype(~20% missing at random): Sample size = 1076
1% 0.24 GEE 0.934 0.836 0.631 0.427 0.261 0.149 0.074 0.041
2% 0.33 GEE 1.00 0.99 0.97 0.93 0.82 0.66 0.51 0.37
3% 0.41 GEE 1 1 0.998 0.993 0.976 0.938 0.85 0.753
4% 0.47 GEE 0.998 0.998 0.998 0.998 0.991 0.984 0.971 0.949
5% 0.53 GEE 1 1 1 1 1 1 1 0.99
~60% subjects have phenotype(~40% missing at random): Sample size = 783
1% 0.24 GEE 0.879 0.737 0.48 0.281 0.137 0.055 0.023 0.008
2% 0.33 GEE 0.992 0.96 0.88 0.744 0.591 0.433 0.293 0.186
3% 0.41 GEE 1 1 0.982 0.945 0.874 0.754 0.602 0.467
4% 0.47 GEE 1 1 1 0.998 0.981 0.95 0.884 0.797
5% 0.53 GEE 1 1 0.999 0.997 0.996 0.982 0.964 0.931
*SD: Standard Deviation. The effect size is expressed in unit of standard deviation of the phenotype.BMC Medical Genetics 2007, 8(Suppl 1):S1 http://www.biomedcentral.com/1471-2350/8/S1/S1
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decrease of the phenotype value with one copy increment
of the allele tested, depends on the MAF of the SNP. For
example, for a SNP explaining 4% of the phenotypic vari-
ation, the effect size is 0.47 times the phenotypic standard
deviation (SD) for a MAF of 0.1, and 0.28 SD for a MAF of
0.5.
Synthetic strategies
Beyond simple examination of individual p-values for sin-
gle tests, the authors of each manuscript developed their
own synthetic strategies to prioritize SNPs that may be
worthy of follow up (results shown in Table 3 of each
manuscript). Many strategies considered results among
similar traits. For example, the Subclinical Working
Group created four subgroups of traits: (1) ankle brachial
index phenotypes, (2) common carotid IMT phenotypes,
(3) internal carotid IMT phenotypes, and (4) multidetec-
tor computed tomography (MDCT) coronary calcification
phenotypes [29]. Within each trait group, SNPs were
ranked according to the proportion of traits with p < 0.01
for both FBAT and GEE in the group. Table 3 in the Sub-
clinical manuscript displays the top 5 ranked SNPs with
highest proportions of significant traits and lowest mean
GEE p-values for each trait group [29]. The Lipids Sub-
group of the Metabolic Working Group decided to focus
on four phenotypes measured in Offspring subjects: apol-
ipoprotein A-I levels measured at exam 4, small low-den-
sity lipoprotein as measured by nuclear magnetic
resonance, mean high-density lipoprotein cholesterol lev-
els over 7 exams, and mean log triglyceride levels over 7
exams [39]. Presenting only those results where at least 3
of the 4 traits had GEE p-value < 0.01, the SNPs were
ranked according to geometric mean of these four traits
[39]. The manuscript presenting results for neurological
traits focused on specific phenotypes within subgroups
Distribution of Minor Allele Frequency for SNPs in Framingham Sample displayed on dbGaP Website Figure 1
Distribution of Minor Allele Frequency for SNPs in Framingham Sample displayed on dbGaP Website. The per-
centage of SNPs (X axis) with MAF of zero and in ranges (0,2], (2,4], ..., (48,50] percent (Y axis) in the Framingham sample of 
1345 subjects is detailed. For example, approximately 2.5–3% of SNPs in the Affymetrix 100K GeneChip had MAF of zero in 
the Framingham sample and about 4% had MAF greater than 16 percent and less than or equal to 18 percent. This distribution 
represents SNPs described on the dbGaP website. The manuscripts only include SNPs with MAF of 10% or more.
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with p < 0.001 in FBAT or GEE results and also other traits
within the subgroup with p < 0.01 [37].
Some results of interest
The main results for each Working Group are presented in
the individual manuscripts of this series. Here we high-
light some results that address some of our expectations.
Overlap of linkage and association results
Whereas strategies for genetic studies have been undergo-
ing substantial changes in recent years, partly due to
changes in the laboratory, we hypothesized that genomic
regions that harbor significant linkage results would also
contain significant association results. One example of the
concordance of linkage and association results was noted
for monocyte chemoattractant protein-1 (MCP1), an
inflammatory marker, where a region of linkage (LOD =
4.96 at chromosome 1, 159 Mb) for MCP1 concentrations
also contains two SNPs on chromosome 1 within the 1.5
support interval for the linkage peak and within 60 kb of
the genes OR10J1  and FCER1A  or OR10J3  (rs4128725
and rs2494250 with p-values in the 10-8 range by FBAT,
≤10-12 by GEE) [33]. We found a similar result for C-reac-
tive protein with a LOD score of 3.28 on chromosome 1
and two significant SNPs (rs2794520 (p = 2.83*10-8) and
rs2808629 (p = 3.19*10-8)) within the 1.5 support inter-
val of this peak [33]. Whereas Lp(a) had the highest LOD
score (LOD = 23.0) at 159.4 Mb, a SNP (rs1591375)
located at 160.7 Mb near this peak had somewhat modest
p-values by comparison (4.37*10-06 by GEE and 0.0045
by FBAT) [39]. However, there were many instances for
which there was no evidence of linkage in the setting of
significant association. Additionally, each manuscript
describes linkage results that are in accord with previously
published linkage results.
SNPs overlapping across phenotypes
We did not expect the same SNPs to appear in many man-
uscripts, as cardiovascular disease is complex and involves
a large and varied number of pathways for its develop-
ment. In contrast, some manuscripts report on correlated
traits. Thus, we examined overlap among the top 500
SNPs associated with the phenotypes across 3 Metabolic
Working Groups: glycemic/diabetes phenotypes, lipid
phenotypes and obesity phenotypes. Of 11 SNPs found in
more than one group, none were found among the top
500 SNPs in all three groups. However, 7 SNPs were
found in the glycemia and obesity groups, 2 in glycemia
and lipid groups and 2 in lipid and obesity groups [38-
40].
Replication of prior associations
In Table 4 of each manuscript, we investigated whether
our results replicated previous reports in the literature.
The 100K chip does not contain many SNPs in well-
known lipid genes, such as APOE. On the other hand, we
found that SNP rs7007797 in the LPL gene was associated
with both HDL and triglycerides [39]; we replicated recent
findings of association of a SNP in the TCF7L2 gene with
diabetes [38]. Strong statistical support was found for the
association of factor VII concentrations with SNP
rs561241 on chromosome 13 (4*10-16) [34], which
resides near the factor VII gene and is in complete linkage
disequilibrium (r2 = 1) with the Arg/Gln FVII SNP previ-
ously shown to account for 9% of the total phenotypic
variance [78]. Similarly, we found associations of circulat-
ing levels of C-reactive protein with a SNP in the gene
encoding C-reactive protein [33]. Two SNPs in SORL 1, a
gene recently related to the risk of Alzheimer's disease
[79], were found to be associated with performance on
tests of abstract reasoning (rs1131497; FBAT p = 3.2 × 
10-6; rs726601; FBAT p = 8.2 × 10-4) [37]. We found that
SNPs (rs2543600 and rs27225364) near the WRN gene
that causes premature aging are associated with age at
death and morbidity-free survival at age 65 years [35]. The
LD between these SNPs and those previously reported in
the WRN gene is unknown as the previously reported
SNPs are not in the HapMap. We found that SNP
rs2478518 in the AGT  gene was associated with both
systolic and diastolic blood pressure [28]. The association
of common variation at the NOS1AP locus with electro-
cardiographic QT interval duration was replicated with p-
values ranging from 0.0001–0.0009 for 4 partially corre-
lated SNPs [27]. In contrast, a number of results reported
Distribution of Affymetrix 100K GeneChip SNPs by distance  from known genes Figure 2
Distribution of Affymetrix 100K GeneChip SNPs by 
distance from known genes. The X axis is the distance 
from known genes and the Y axis is the number of SNPs 
according to each distance. Blue represents monomorphic 
SNPs, maroon is for SNPs with MAF < 10% and green is for 
SNPs with MAF ≥ 10%.
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in the literature were not replicated in our results. For
example, we did not find significant SNPs in ACE associ-
ated with blood pressure [28]. PPARG P12A (rs1801282)
was not associated with diabetes or related traits including
body mass index [38]. Some of these 'negative' results may
be due to low power or low LD between a SNP reported in
the literature and SNPs on the 100K chip.
We have also identified a few results that are biologically
compelling, although replication of the SNP association is
warranted. For example, we found that a SNP
(rs1158167) near the CST3 gene was highly associated
with serum cystatin-C levels (GEE p-value = 8.5*10-09)
[42]. This SNP explained 2.5% of the variation in serum
cystatin-C levels in our data and has been previously
reported to be associated with cystatin-C. These results are
presented in more detail in the Renal Endocrine Working
Group manuscript [42].
Replication of results from other genome-wide studies
While we have been preparing this series of manuscripts,
several genome-wide studies have been published [80-
86]. Some results in our analyses support results reported
in these recent studies. For example, we find significant
associations for coronary heart disease, cardiovascular dis-
ease and coronary artery calcium [29,30] in the same
chromosomal region on 9p recently reported to be associ-
ated with myocardial infarction by Helgadottir et al. [82]
and McPherson et al. [83]. While our results need to be
compared more closely with results being reported by
other genome-wide studies, this example provides evi-
dence that our results replicate strong associations from
other genome-wide studies.
Discussion
We have presented a brief description of the methods and
a few selected results derived from analyses of the 100K
Affymetrix GeneChip with a large number of FHS traits,
ranging from CVD events and subclinical measures to tra-
ditional cardiovascular risk factors of diabetes, lipid lev-
els, blood pressure and also including more novel
biomarker measures that reflect modern hypotheses, such
as the role of inflammatory pathways in the development
of CVD. We have also reported on a number of neurolog-
ical, renal, cancer and aging traits, including longevity
(age at death) and bone mass and structure. None of these
manuscripts provide a comprehensive report. Rather, the
purpose of this set of manuscripts is to provide a brief
Observed versus Expected p-values (-log base 10 scale) for Mean Fasting Glucose in Offspring Exams 1 to 7 (Left) and for Mean  Fasting High Density Lipoprotein in Offspring Exams 1 to 7 (Right) Figure 3
Observed versus Expected p-values (-log base 10 scale) for Mean Fasting Glucose in Offspring Exams 1 to 7 
(Left) and for Mean Fasting High Density Lipoprotein in Offspring Exams 1 to 7 (Right). Blue dots are for GEE and 
red dots for FBAT.BMC Medical Genetics 2007, 8(Suppl 1):S1 http://www.biomedcentral.com/1471-2350/8/S1/S1
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summary of the results and to introduce readers to the
data posted on the dbGaP website http://
www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
study.cgi?id=phs000007. We note that the genotypes in
this sample have also been evaluated by Drs. Michael
Christman and Alan Herbert. Some of their results are
reported on line as described by Herbert et al. [87].
Several aspects of our investigation merit comment. First,
the present investigation represents a comprehensive
GWAS analysis of numerous phenotypes in a large com-
munity-based cohort. To our knowledge, it is the largest
GWAS performed in an observational cohort in terms of
the number of phenotypes analyzed and web posted. Sec-
ond, we exploited the phenotypic diversity and richness
of the Framingham Offspring Study database to analyze a
set of phenotypes that were for the most part collected by
detailed, direct measurements of study participants. Fur-
ther, many of the phenotypes are quantitative traits. Phe-
notypes have been broadly categorized into seventeen
different domains for manuscripts in this supplement. It
is noteworthy that key risk factor phenotypes, such as
blood pressure and lipid levels, were collected at multiple
examinations, and thus we were able to conduct analyses
using time-averaged traits, maximizing the scientific yield
from the longitudinal prospective design of our cohort
study. Further, several recently collected phenotypes, in
particular biomarkers and imaging measures, were col-
lected using highly reproducible, state-of-the-art modali-
ties. Correlated phenotypes facilitated the assessment of
pleiotropy by seeking associations of SNPs with such phe-
notypes. These investigations occurred primarily among
the variables in each individual manuscript. Finally, for
most phenotypes, there was evidence for a significant her-
itable component from FHS or other studies. We acknowl-
edge that some phenotypic domains may represent
analytical constructs, rather than truly distinct groups
from a biological standpoint.
Third, we have web-posted the results of all analyses on
autosomes on dbGaP, including results without statistical
evidence of association, so that investigators world-wide
can access the data freely and mine them in silico for
hypothesis generation, inclusion in meta-analysis, and
direct comparisons with their own results. In addition to
the freely posted aggregate results, participant-specific
genotypic and phenotypic data are available for distribu-
tion for further analyses to approved scientific investiga-
tors world-wide via the NCBI/NHLBI and consistent with
Framingham Study data distribution policies (see http://
www.nhlbi.nih.gov/about/framingham/policies/
index.htm). For the purpose of publication, reference to
these analyses may be made by referring to either the
appropriate manuscript or the specific URL for web-
posted data. Fourth, the simultaneous and full-disclosure
release (on the web) of all association and linkage results
of phenotypes encompassing at least 17 different domains
in a cohesive and comprehensive manner signifies the tre-
mendous teamwork of numerous FHS investigators, stat-
isticians, programmers, and others. Most importantly, this
effort would not be possible without the full cooperation
and commitment of the FHS participants, who continue
to attend Study examinations in an effort to further the
scientific knowledge of factors that lead to heart disease
and other traits.
Fifth, as in any genome-wide association study with a
large number of SNPs, most results that are considered
statistically significant by a conventional p < 0.05 may be
falsely positive; so it is difficult to decide what results are
important. Not only do we have a large number of statis-
tical tests for each phenotype, but we also have numerous
phenotypes. Thus, considering multiple testing in the
interpretation of results is of paramount importance.
There are several approaches to address the issue of multi-
ple testing, such as Bonferroni correction, permutation
testing and false discovery rates. To conduct permutation
testing for all of the traits that we considered is prohibi-
tively time-consuming, particularly in preserving herita-
bility of the traits with family data. Further, with
correlated traits it is difficult to decide what traits should
be included in a permutation testing strategy. One
approach to controlling the false-positive rate in genome-
wide association studies is to set a stringent threshold for
declaring statistical significance. According to the report
of the International HapMap Consortium, complete test-
ing of common variants (MAF > 0.05) in each 500 kb is
equivalent to performing 150 independent tests in white
populations of European descent [88]. Using this guide
and given that there are about 3000 Mb in the human
genome, we would estimate that there are approximately
900,000–1,000,000 independent tests if testing all com-
mon variants in the genome. A conservative Bonferroni
correction using this number of tests (0.05/1,000,000)
yields an approximate threshold of genome-wide signifi-
cance to be 5*10-8. Thus, for a single trait, one could use
this threshold. Several results do fall below this threshold
(Table 5 of the Overview). In considering these results, we
note that our sample size of 1345 biologically related sub-
jects is relatively small for detecting genetic variants of
modest effect. We also note that we have a large number
of correlated traits, including the same traits with different
covariate adjustments. Further, we have already observed
that our GEE results have an excess number of small p-val-
ues. Thus, we are hesitant to regard any result reported in
our manuscripts as significant at a genome-wide level. We
believe these findings are best regarded as hypothesis-gen-
erating. The determination of what constitutes genome-
wide significance is challenged both by theoretical consid-
erations as well as practical ones. Without pursuing moreBMC Medical Genetics 2007, 8(Suppl 1):S1 http://www.biomedcentral.com/1471-2350/8/S1/S1
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computationally intensive analyses, it is thus difficult to
provide specific advice regarding what SNPs are most
important. It may be safer to assume that most of the
small p-values are likely to be false positives and that
replication of our results in other independent samples
is of critical importance. We proceed with presentation
of full-disclosure results to encourage readers to pursue
such studies.
Sixth, we note that use of the 80% genotyping call rate is
unusually liberal by today's standards in GWAS. We used
this threshold in these manuscripts to be inclusive, rather
than exclusive, in a first look such as this. We recognize
that this threshold may permit consideration of some
results that could be spurious due problems with genotyp-
ing. However, a limitation of our genotypes is that the
genotype calls were made with the DM algorithm, which
is less precise than those that have recently been intro-
duced. At this time, we are unable to apply more accurate,
reliable genotyping calls [89], as we do not have access to
the source data. Further, we found that the choice of the
80% threshold versus a more conservative one had little
effect upon p-value distributions. Finally, all results,
regardless of genotyping call rate, are posted on the
dbGaP website and thus, investigators can evaluate for
themselves what they believe to be the more valid results
from this study.
Seventh, in our analyses we found that the GEE results
appear to have an excess of significant results. We suspect
that one reason is low MAF. Also, given the small sample
of at most 1345 subjects, we would expect only 13–14
individuals to have the minor homozygote. Thus, we lim-
ited the results that we present in the manuscripts to those
SNPs with MAF = 10%. Further analyses have indicated
that use of a linear mixed effects model such as incorpo-
rating a SNP as a covariate in a regression model with
proper correlation structure for the error terms that fully
represent the familial correlations remedies this problem
and has a valid type I error rate in simulated data.
Eighth, coverage of LD is incomplete with the 100K scan.
Nicolae et al. report that the Affymetrix 100K GeneChip
includes fewer SNPs in coding and more SNPs in inter-
genic regions than represented on the HapMap [90]. Fur-
ther, our sample size is modest. These two facts combined
likely limit the power for detection of associations with
several traits in these data. For instance, while we noted
modest to high heritability of numerous phenotypes,
underscoring the contribution of additive genetic effects
to interindividual variation in these traits, we did not find
significant low p-values for several heritable traits in rela-
tion to the SNPs evaluated. Factors contributing to this
observation included both the limited coverage of the
Affymetrix 100K GeneChip as well as the possibility that
some of the less significant p-values (example between
0.05 and 10-5) may represent true positive findings. The
limited power to detect SNPs of small effect sizes offered
by the analysis of our relatively modest sample size of
~1300 participants contributes to this phenomenon as
well; we only have high power to detect a SNP explaining
4% or more of the phenotypic variance in the population-
based GEE association test; the power of FBAT and vari-
ance component linkage analysis is even lower.
Additionally, for several of the analyzed phenotypes we
did not observe any overlap between the top SNP-pheno-
type associations noted in GEE and FBAT analyses. The
inherent differences in the two analytical methods espe-
cially in the context of the modest sample sizes, particu-
larly for FBAT with small numbers of informative trios,
may contribute to this phenomenon. FBAT is limited by
the number of informative transmissions and although
we suspect that there is little population stratification in
our sample [76], GEE is limited by potential bias due to
stratification. Furthermore, for several phenotypes the
SNPs associated with the top LOD scores in linkage anal-
yses were not among the top 50 SNPs in association anal-
yses (GEE or FBAT).
Table 5: Associations achieving nominal genome wide significance, p < 5*10-8 across the 17 phenotype working groups
Phenotype working 
group/manuscript
Trait SNP rs ID* Chr Physical location (bp) GEE P-value FBAT P-value IN/NEAR gene
Select biomarkers [33] Monocyte chemoattractant protein-1 rs2494250 1 156,091,324 1.0*10-14 3.5*10-8 FCER1A, OR10J3
Monocyte chemoattractant protein-1 rs4128725 1 156,219,032 3.7*10-12 3.3*10-8 OR10J1
C-reactive protein average exams 2,6,7 rs2794520 1 156,491,889 2.8*10-8 4.3*10-5 CRP
C-reactive protein average exams 2,6,7 rs2808629 1 156,489,869 3.2*10-8 4.8*10-5 CRP
Kidney/Endocrine [42] Cystatin C rs1158167 20 23,526,189 8.5*10-09 0.006 CST9L|CST9|CST3
Diabetes [38] 28-year mean fasting plasma glucose rs2722425 8 40,603,396 2.0*10-8 0.005 ZMAT4
Sleep and circadian [26] Epworth sleepiness scale rs1823068 5 58,711,806 2.5*10-8 0.069 PDE4D
Neurology [37] Total Cerebral Brain Volume (ATCBV) rs1970546 20 59287333 4.0*10-8 0.005 CDH4
Hemostatic factors [34] Factor VII rs561241 13 112,808,035 4.5*10-16 3.4*10-4 F7
The following phenotype working groups did not have any traits achieving nominal genome-wide significance: echocardiography, flow-mediated dilation and exercise tolerance 
testing; blood pressure and tonometry; subclinical cardiovascular disease; cardiovascular outcomes; cancer; electrocardiography and heart rate variability; pulmonary function 
testing; aging; bone; lipids; obesityBMC Medical Genetics 2007, 8(Suppl 1):S1 http://www.biomedcentral.com/1471-2350/8/S1/S1
Page 15 of 19
(page number not for citation purposes)
Ninth, we were limited in our ability to replicate genetic
variants previously reported to be associated with pheno-
types in our database because specific coverage of such
genetic variation in these candidates was limited in the
Affymetrix 100K GeneChip. We view such analyses as
more illustrative of the potential utility of our GWAS,
rather than as definitive evidence for or against an associ-
ation described with a putative candidate gene in the pub-
lished literature.
Our data do suggest several interesting biological candi-
dates among the SNPs most strongly associated with dif-
ferent traits in the various analytical approaches. The
strongest and most clear-cut of the associations were for
those phenotypes that represent the direct protein product
of a gene. Examples include the association of CRP con-
centrations with SNPs in the CRP gene (Benjamin et al. in
this series [33]) and factor VII levels with SNP rs561241
on chromosome 13 (Yang et al. in this series [34]). Thus,
while it is difficult to point to any result as definitive,
those results for which we find some evidence of replica-
tion of associations found in the literature are regarded as
worthy of further research.
Finally, the Framingham Study participants were white of
European descent and predominantly middle-aged to eld-
erly. Hence, the genetic associations may not be generaliz-
able to other ethnicities/races or to younger individuals.
Conclusion
In summary, the results from the FHS 100K association
and linkage studies described herein and posted on the
NCBI website provide a GWAS resource for investigators.
We have presented a description of the methods and gen-
eral strategies used for analysis of the 100K Affymetrix
GeneChip in relation to a broad range of traits measured
in the FHS. Brief descriptions of results of these analyses
are provided a series of 17 manuscripts, with results for all
autosomal SNPs genotyped successfully displayed at
http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
study.cgi?id=phs000007. Interested investigators can also
access the data through a standing protocol, described at
http://www.nhlbi.nih.gov/about/framingham/policies/
index.htm. Key to interpretation of these results is replica-
tion and evaluation of these results in other cohorts and
ultimately, functional studies. We encourage investigators
to examine the results and to pursue the genetic signals
therein in their own cohorts. In the near future we will
provide results and data from approximately 550,000
SNPs on more than 9000 participants from three genera-
tions in the FHS SNP Health Association Resource
(SHARe) project. Data will be available to qualified inves-
tigators through an application process to dbGaP. It is our
hope that the results from these two genome-wide associ-
ation studies will lead to a much deeper understanding of
the role of common genetic variation in the development
of cardiovascular disease and its risk factors.
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